<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03941366</url>
  </required_header>
  <id_info>
    <org_study_id>866142</org_study_id>
    <nct_id>NCT03941366</nct_id>
  </id_info>
  <brief_title>Treatment of Adenocarcinoma of the Rectum With Transanal Local Excision for Complete Responders</brief_title>
  <official_title>Treatment of T2-T3/NO-N+ Adenocarcinoma of the Rectum by Neoadjuvant Chemotherapy (FOLFOX) Followed by Preoperative Chemo (5FU/Capecitabine)-Radio Therapy (CRT) With Transanal Local Excision for Complete Responders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascension South East Michigan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascension South East Michigan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current standard of care for rectal cancer has diminished local recurrence and enhanced&#xD;
      survival. Quality of life, however, remains poor for many patients and the probability of&#xD;
      distant recurrence is high. In this study, we will attempt to reduce the distant recurrence&#xD;
      rate and improve quality of life by making changes in the timing and administration of&#xD;
      chemotherapy and radiation and doing less invasive rectal surgery when indicated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to determine if neo-adjuvant FOLFOX therapy and lengthening the&#xD;
      time interval between neo-adjuvant chemotherapy and transanal local excision will increase&#xD;
      the percentage of patients with pathologic complete remission.&#xD;
&#xD;
      This is a prospective pilot study to examine the impact of two variables: 1) addition of&#xD;
      neo-adjuvant FOLFOX chemotherapy, and 2) increasing the time interval between completion of&#xD;
      chemo-radiotherapy and subsequent surgery, on the rate of achieving pathologic complete&#xD;
      remission with avoidance of radical resection while maintaining an excellent local control&#xD;
      with improvement of quality of life.&#xD;
&#xD;
      All procedures in this study are standard of care, the study question relates to the use of&#xD;
      neo-adjuvant FOLFOX and the timing between the end of radiation and surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 26, 2016</start_date>
  <completion_date type="Anticipated">January 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>All patients in the trial receive the intervention and are followed prospectively.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Complete remission</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of patients who achieve complete remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial remission</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of patients who achieve partial remission</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease progression</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of patients with disease progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Local resection</measure>
    <time_frame>18 months</time_frame>
    <description>Percent of patients who require local resection only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient quality of life</measure>
    <time_frame>18 months</time_frame>
    <description>Quality of life score on questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient health status</measure>
    <time_frame>18 months</time_frame>
    <description>Patient self-reported health status</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Chemotherapy and Follow-up Surgery</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients will receive standard of care therapy and based upon their response will either receive transanal local resection or full resection, based on pathologic response.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Standard of care chemotherapy with the change for avoidance of extensive surgery</intervention_name>
    <description>All treatments (chemotherapy, radiation, surgery) are standard of care; however, the timing of the procedures is altered to allow for the possibility of local excision instead of more extensive surgery.</description>
    <arm_group_label>Neoadjuvant Chemotherapy and Follow-up Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age â‰¥ 18 years&#xD;
&#xD;
          2. Diagnosis of rectal invasive adenocarcinoma&#xD;
&#xD;
          3. Tumor in the low or mid rectum (up to 11 cm from the anal verge)&#xD;
&#xD;
          4. Clinical stage T3/N0-N1M0. Patients with low T2 who will need abdominal perineal&#xD;
             resection are also eligible.&#xD;
&#xD;
        1. Clinical staging will be estimated based on the combination of the following&#xD;
        assessments:&#xD;
&#xD;
          1. Physical examination by the primary surgeon&#xD;
&#xD;
          2. Computed Tomography or Positron Emission Tomography/Computed Tomography scan of chest,&#xD;
             abdomen and pelvis&#xD;
&#xD;
          3. Pelvic MRI and endoscopic ultrasound&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Less than 18 years of age&#xD;
&#xD;
          -  Do not complete informed consent&#xD;
&#xD;
          -  Pregnant women&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Lisa C Miller, BA</last_name>
    <phone>313-343-3166</phone>
    <email>lisa.miller4@ascension.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan M Szpunar, PhD</last_name>
    <phone>313-343-7838</phone>
    <email>susan.szpunar@ascension.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ascension St. John Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa C. Miller, BA</last_name>
      <phone>313-343-3166</phone>
      <email>lisa.miller@ascension.org</email>
    </contact>
    <contact_backup>
      <last_name>Amr Aref, MD</last_name>
      <phone>313-343-3166</phone>
      <email>amr.aref@ascension.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 5, 2019</study_first_submitted>
  <study_first_submitted_qc>May 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 7, 2019</study_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ascension South East Michigan</investigator_affiliation>
    <investigator_full_name>Amr Aref</investigator_full_name>
    <investigator_title>Director, Radiation Oncology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

